Hennion & Walsh Asset Management, Inc. Coherus Bio Sciences, Inc. Transaction History

Hennion & Walsh Asset Management, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$7.17 - $13.87 $53,524 - $103,539	-7,465 Reduced 5.35%	132,137 $1.27 Million
Q2 2022 Jul 19, 2022	SELL	$5.86 - $13.23 $38,013 - $85,823	-6,487 Reduced 4.44%	139,602 $1.01 Million
Q1 2022 Apr 26, 2022	SELL	$10.92 - $16.41 $57,417 - $86,283	-5,258 Reduced 3.47%	146,089 $1.89 Million
Q4 2021 Feb 14, 2022	SELL	$15.81 - $18.99 $218,778 - $262,783	-13,838 Reduced 8.38%	151,347 $2.42 Million
Q3 2021 Nov 12, 2021	SELL	$12.68 - $17.79 $46,167 - $64,773	-3,641 Reduced 2.16%	165,185 $2.66 Million
Q2 2021 Aug 13, 2021	BUY	$12.95 - $15.41 $301,825 - $359,160	23,307 Added 16.02%	168,826 $2.34 Million
Q1 2021 May 17, 2021	BUY	$14.42 - $21.39 $2.1 Million - $3.11 Million	145,519 New	145,519 $2.13 Million

130

67.8M

1.68M

91.8K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $71.5M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.